UMB Bank N A MO boosted its stake in Becton, Dickinson and Company (NYSE:BDX) by 9.6% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 72,761 shares of the medical instruments supplier’s stock after acquiring an additional 6,352 shares during the quarter. UMB Bank N A MO’s holdings in Becton, Dickinson and were worth $14,196,000 as of its most recent filing with the SEC.

Other institutional investors also recently added to or reduced their stakes in the company. North Star Investment Management Corp. lifted its holdings in Becton, Dickinson and by 3.4% in the 1st quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock valued at $101,000 after purchasing an additional 18 shares in the last quarter. Almanack Investment Partners LLC. purchased a new position in Becton, Dickinson and in the 1st quarter valued at $105,000. Parkside Financial Bank & Trust lifted its holdings in Becton, Dickinson and by 1.4% in the 1st quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock valued at $116,000 after purchasing an additional 9 shares in the last quarter. QCI Asset Management Inc. NY lifted its holdings in Becton, Dickinson and by 9.2% in the 1st quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock valued at $130,000 after purchasing an additional 60 shares in the last quarter. Finally, Financial Architects Inc lifted its holdings in Becton, Dickinson and by 8.0% in the 2nd quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock valued at $142,000 after purchasing an additional 54 shares in the last quarter. 87.43% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company (NYSE:BDX) opened at 202.20 on Wednesday. The firm has a 50-day moving average price of $200.08 and a 200 day moving average price of $191.02. Becton, Dickinson and Company has a 52-week low of $161.29 and a 52-week high of $206.63. The firm has a market capitalization of $46.01 billion, a P/E ratio of 58.56 and a beta of 1.06.

Becton, Dickinson and (NYSE:BDX) last released its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The firm had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.06 billion. During the same period in the prior year, the business posted $2.35 earnings per share. The firm’s revenue for the quarter was down 5.1% compared to the same quarter last year. Analysts forecast that Becton, Dickinson and Company will post $9.46 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be issued a $0.73 dividend. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.44%. Becton, Dickinson and’s dividend payout ratio (DPR) is 83.43%.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/13/becton-dickinson-and-company-bdx-shares-bought-by-umb-bank-n-a-mo.html.

In other news, insider Gary M. Cohen sold 15,512 shares of the firm’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $203.77, for a total value of $3,160,880.24. Following the transaction, the insider now directly owns 95,781 shares in the company, valued at approximately $19,517,294.37. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Ellen R. Strahlman sold 9,283 shares of the firm’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $198.21, for a total value of $1,839,983.43. Following the completion of the transaction, the insider now owns 26,638 shares in the company, valued at $5,279,917.98. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 75,904 shares of company stock worth $15,242,688. Company insiders own 1.40% of the company’s stock.

A number of brokerages have weighed in on BDX. Piper Jaffray Companies restated a “buy” rating and issued a $213.00 price objective on shares of Becton, Dickinson and in a report on Tuesday. BidaskClub upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Monday, August 14th. Cowen and Company reiterated a “buy” rating and set a $230.00 price target on shares of Becton, Dickinson and in a report on Monday, August 14th. Barclays PLC reiterated an “equal weight” rating and set a $210.00 price target (up previously from $205.00) on shares of Becton, Dickinson and in a report on Thursday, August 10th. Finally, Stifel Nicolaus reiterated a “buy” rating on shares of Becton, Dickinson and in a report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $196.93.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.